Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Moliterno DJ, et al. Among authors: topol ej. Am J Cardiol. 1995 Mar 15;75(8):559-62. doi: 10.1016/s0002-9149(99)80616-x. Am J Cardiol. 1995. PMID: 7887377 Clinical Trial.
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ; EPIC Investigators; EPILOG investigators; EPISTENT investigators. Kereiakes DJ, et al. Among authors: topol ej. Am J Cardiol. 2002 Sep 15;90(6):628-30. doi: 10.1016/s0002-9149(02)02568-7. Am J Cardiol. 2002. PMID: 12231090 Clinical Trial. No abstract available.
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Among authors: topol ej. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, Topol EJ. Ross MJ, et al. Among authors: topol ej. J Am Coll Cardiol. 2003 Sep 17;42(6):981-8. doi: 10.1016/s0735-1097(03)00913-6. J Am Coll Cardiol. 2003. PMID: 13678916 Free article. Clinical Trial.
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators. Chan AW, et al. Among authors: topol ej. J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95. doi: 10.1016/s0735-1097(03)00944-6. J Am Coll Cardiol. 2003. PMID: 14522478 Free article. Clinical Trial.
1,205 results